MARKER THERAPEUTICS, INC.: 10-K filed 2013-05-15
What MARKER THERAPEUTICS, INC. reported in its annual report filed 2013-05-15 (fiscal FY 2012): 15 published measures, 33 facts as tagged in accession 0001554757-13-000319.
This filing
- Form
- 10-K (annual report)
- Filed
- 2013-05-15
- Fiscal period
- fiscal FY 2012
- Accession
- 0001554757-13-000319 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | 104,212 | USD | |
| At 2011-12-31 | 307,921 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | -5,666,597 | USD | |
| At 2011-12-31 | -3,460,360 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-12-31 | -5,857,943 | USD | 366 |
| 1999-07-27 to 2012-12-31 | -49,580,159 | USD | 4907 |
| 2011-01-01 to 2011-12-31 | -2,028,941 | USD | 365 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1999-07-27 to 2012-12-31 | 218,626 | USD | 4907 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-12-31 | 1,365,543 | USD | 366 |
| 1999-07-27 to 2012-12-31 | 16,265,460 | USD | 4907 |
| 2011-01-01 to 2011-12-31 | 1,536,585 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1999-07-27 to 2012-12-31 | 204,747 | USD | 4907 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-12-31 | 2,440,228 | USD | 366 |
| 1999-07-27 to 2012-12-31 | 13,115,620 | USD | 4907 |
| 2011-01-01 to 2011-12-31 | 1,261,983 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | 104,212 | USD | |
| At 2011-12-31 | 340,212 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | 5,770,809 | USD | |
| At 2011-12-31 | 3,800,572 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-12-31 | 1,057,430 | USD | 366 |
| 1999-07-27 to 2012-12-31 | 6,968,595 | USD | 4907 |
| 2011-01-01 to 2011-12-31 | 203,725 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | 76,402,958 | shares | |
| At 2011-12-31 | 52,073,460 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | -61,648 | USD | |
| At 2011-12-31 | -60,528 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-12-31 | 1,012,116 | USD | 366 |
| 1999-07-27 to 2012-12-31 | 3,929,352 | USD | 4907 |
| 2011-01-01 to 2011-12-31 | 305,714 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1999-07-27 to 2012-12-31 | 213,227 | USD | 4907 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-12-31 | 555,000 | USD | 366 |
| 1999-07-27 to 2012-12-31 | 10,860,575 | USD | 4907 |
| 2011-01-01 to 2011-12-31 | 683,450 | USD | 365 |
Inspect the source
- Entity
- MARKER THERAPEUTICS, INC. / CIK 0001094038
- Captured
- 2026-09-20T05:22:11.393Z
- SEC response SHA-256
11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))